Eisai & Biogen update on regulatory review of MAA for lecanemab for early Alzheimer’s disease by the European Commission
Eisai Co., Ltd. and Biogen Inc., a leading biotechnology company, announced an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as a treatment for early AD (mild cognitive impairment and mild dementia due to …